

The Power of Debate

Debates hold transformative power in the field of rheumatology and autoimmunity, offering an unparalleled platform to challenge established norms and ignite forward-thinking ideas. At CORA 2025, attendees can dive into 21 dynamic debates, each designed to address some of the most pivotal and thought-provoking issues in rheumatology today. This unique format brings together leading experts to argue opposing views on urgent clinical, diagnostic, and therapeutic questions. The debates stimulate critical thinking, inspire innovative approaches, and ultimately push the field towards more effective patient-centered solutions.

[Join CORA 2025](#)

What Should We Use As the First-Line Treatment for RA?

Debate 1

Zoltan Szekanecz (Hungary)
b/tsDMARDs

Andrea Rubbert-Roth (Switzerland)
MTX

Are the New Classification Criteria a Step Forward in the Management of Antiphospholipid Syndrome?

Debate 2

Savino Sciascia (Italy)

Yes

Jaume Alijotas-Reig (Spain)

No

LN Treatment: Early Combination vs. Standard Treatment

Debate 3

Ioannis Parodis (Sweden)

Early Combination

Laurent Arnaud (France)

Standard Treatment

The Use of Medical Cannabis in Rheumatic Pain Management: Valid Option or Unproven Treatment?

Debate 4

Howard Amital (Israel)

Valid Option

Winfried Häuser (Germany)

Unproven Treatment

Beyond Physical Examination – How to Approach to RA Management: Joint

Ultrasound or Synovial Biopsy?

Debate 5

Maria-Antonietta D'Agostino (Italy)

Joint Ultrasound

Felice Rivellese (United Kingdom)

Synovial Biopsy

Mepolizumab in EGPA: Does One Size Fit All?

Debate 6

Benjamin Terrier (France)

Yes

Giacomo Emmi (Italy)

No

TNFi or IL17i for the Slowing the Radiographic Progression in Spondyloarthritis?

Debate 7

Mikkel Østergaard (Denmark)

TNFi

Salvatore D'Angelo (Italy)

IL17i

Gut Microbiome in Rheumatic Diseases: Revolutionary or Fake News?

Debate 8

Francesco Ciccia (Italy)
Revolutionary

Zoltan Szekanecz (Hungary)
Fake News

CAR-T Cells in Rheumatic Diseases: Game-Changer or Just a Buzz?

Debate 9

Laura Bucci (Germany)
Game-Changer

Marit Stockfelt (Sweden)
Just a Buzz

Is Seronegative Sjogren Syndrome a Distinct Clinical Entity? & Should Hydroxychloroquine Be Used in Patients With Sjogren Syndrome?

Debate 10

Roberto Gerli (Italy)
Yes

Athanasios Tzioufas (Greece)

No

Early Biologic Treatment in Systemic Lupus: Necessary or Overemphasized?

Debate 11

Mariele Gatto (Italy)

Necessary

Chris Wincup (UK)

Overemphasized

Is Hematopoietic Stem Cell Transplantation (Really) a Valid Option for Patients with Systemic Sclerosis?

Debate 12

Dominique Farge (France)

Yes

Oliver Distler (Switzerland)

No

Can We Give Targeted Therapies in

Patients With Cancer?

Debate 13

Eden Sebbag (France)

Yes

Zoltan Szekanecz (Hungary)

No

Are IPAF and UCTD Two Clinical Variants of the Same Systemic Autoimmune Disorder?

Debate 14

Marco Sebastiani (Italy)

Two Clinical Variants

Szilvia Szamosi (Hungary)

The Same

Do JAK Inhibitors Aggravate Comorbidities Such As Cardiovascular Disease and Cancer?

Debate 15

Serena Bugatti (Italy)

Yes

Ernest Choy (UK)

No

Should We Treat preRA/at Risk RA Individuals or Not?

Debate 16

Andrew Cope (UK)

Yes

György Nagy (Hungary)

No

Is It Common To Achieve the T2T goals in SLE Patients?

Debate 17

Marta Mosca (Italy)

Yes

Anisur A. Rahman (UK)

No

Axial Psoriatic Arthritis and axSpA: To Lump or to Split

Debate 18

Phillip Sewerin (Germany)

To Lump

Ennio Lubrano (Italy)

To Split

Should Immunosuppressive Drugs be Used in All Patients With the Limited Cutaneous Form of SSc?

Debate 19

Marco Matucci-Cerinic (Italy)

Yes

Yannick Allanore (France)

No

Is It Safe to Use Low-Dose Glucocorticoids in GCA?

Debate 20

Francesco Muratore (Italy)

Yes

Peter Villiger (Switzerland)

No

Transition from Psoriasis to Psoriatic Arthritis: Are We getting Closer?

Debate 21

Alen Zabotti (Italy)

Yes

Dennis McGonagle (UK)

No